AI skills upgrading biopharma leaders' performance

Image Credit: Quantzig

Announcement 

Since AI has entered the global market across all sectors, it has initially been met with hesitation among biopharma companies. Today, AI is transforming the traditional methods and shifting the nature of leadership at every stage in biopharma. The executives can lead with the help of AI, then just adapt to the same. The AI agents have transitioned from conceptualising to being equipped as a tool, which is having the highest impact on the biopharma companies. Apart from R&D and operations, the executive leadership has also emphasised that technologies like generative AI reframe the skills, mindset and responsibilities of current C-suite leaders.

At Accenture, the research team and global life sciences practices work with the world’s largest pharmaceutical industries. With this, we can observe how the role of the leadership is transitioning consistently in the companies, having increasing pressure to be more flexible, patient-centric and quick in their operations. One of the executives said, “We’ll be the last generation to only lead humans. As the future is the partnership between agents and humans.”

AI Benefits to Executive Teams

The AI is quick enough to be positioned as a key driver of the streamlining of regulatory review processes, enterprise value in biopharma, improving drug discovery, and lastly, transitioning the way clinical trials are organised. The AI agents or ‘twins’ best fuel the decision-making of the genuine executives and deliver the precious and useful data that precise leadership potential. The AI tools and agents are elevating or automating the traditional long-standing time consumption of responsibilities like budget management, operational forecasting, and issue analysis.  These responsibilities are all information-based, knowledge-intensive parts that involve receiving and recording data, documenting and information data that keeps an eye on processes and analyses details. The automation improves precision and speed to perform these responsibilities.

What makes biopharma leaders truly skilled?

According to the CEO of AI twins, the skills that their C-suite needs to lead in the coming years ahead are togetherness (one power), think AI that is precise and demonstrates the data, adapt to manage flexibility and be quick in operations. The new leadership thinks that AI is not just a tech decision but a challenge to the leadership. The industries that are flourishing will be the ones to make the place for consistent learning, experimentation and curiosity. Being an AI twin of one CEO, stated, ‘the suppleness is mostly about proactive preparation than just reaction.’